Locoregionally Advanced Paranasal Sinus Carcinoma: Favorable Survival With Multimodality Therapy

Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ‐preservation approach in patients with paranasal sinus carcinoma

“…Our results of a 32% CR rate if pathologic CRs are taken into account and a 37.5% progression-free survival rate at 2 years certainly are not superior to the results described above (although different populations were treated) or the results reported to date with induction chemotherapy followed by surgery and concomitant chemo-RT, 19,20 although it is difficult to compare Phase II trials. Despite the fact that these latter regimens are highly aggressive, introducing patient selection as an important covariate in treatment outcome, they have not resulted in permanent central nervous system toxicity like the cerebral ischemic episodes that were experienced by our patients.…”

“…18 Induction cisplatin-based chemotherapy followed by surgical excision or/and postoperative RT has resulted in CR and overall response rates in the range of 30 -40% and 80 -90%, respectively. 17,18 High long-term disease control and survival rates in the range of 70 -90% were reported in two small, retrospective, consecutive series by investigators from the University of Chicago 19,20 in which a combination, neoadjuvant, cisplatin-based regimen was used followed by surgery and-or concomitant chemo-RT. The University of Chicago group previously reported a response rate of 80% (CR rate, 37.5%); a local control rate of 76.1% at 5 years and 10 years; noteworthy 5-year and 10-year survival rates of 72.7% and 53.9%, respectively; and a 66.6% disease-free survival rate at both 5 years and 10 years 20 with neoadjuvant cisplatin/5-fluorouracil (5-FU) chemotherapy followed by standard surgical resection and adjuvant, concomitant chemo-RT with a 1 week on/1 week off regimen using cisplatin, 5-FU, and hydroxyurea or standard RT, whereas Choi et al 21 reported a 94% CR rate and a 50% OS rate in 17 patients who were treated with hyperfractionated, concomitant chemo-RT.…”

“…Induction cisplatin-based chemotherapy followed by surgical excision or/and postoperative RT has resulted in complete and overall response rates in the range of 30 -40% and 80 -90%, respectively. 17,18 High long-term disease control and survival rates in the range of 70 -90% have been reported in two small, retrospective, consecutive series by investigators from the University of Chicago 19,20 in which a neoadjuvant cisplatin-based regimen was used followed by surgery and/or concomitant chemo-RT. Finally, in a small series, Choi et al 21 reported a high complete response (CR) rate and modest long-term survival with concomitant, hyperfractionated chemo-RT.…”

Squamous cell carcinoma of the maxillary sinus: A Tata Memorial Hospital experience

“…In one series 92% disease free survival was reported at a follow-up of 55 months following neoadjuvant chemotherapy. [14] Our experience with neoadjuvant chemotherapy was limited, however, two of our patients survived for 31 and 58 months. Similarly, use of preoperative radiotherapy with concomitant intra-arterial chemotherapy has been reported with improved outcomes, but larger studies are needed to confirm these results.…”

A clinical study of multimodal treatment for orbital organ preservation in locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinus

“…With continuing improvement in the desired quality of life among patients with head and neck cancer, multimodal treatment comprising radiochemotherapy and minimally invasive surgery to protect organ function is increasingly being accepted by patients. Some studies of ICT followed by CCRT for the treatment of patients with advanced sinonasal tumours have been conducted in other countries (22)(23)(24), but relevant research on multimodal treatment of advanced sinonasal tumours for orbital organ preservation has rarely been reported. In 1998, Harrison et al (25) applied delayed fractionated radiotherapy technology in combination with cisplatin in a Phase II clinical trial for patients with nonresectable T4 nasal cavity and paranasal sinus tumours, with 3-year OS and LCR reaching 42% and 78%, respectively.…”